Trastuzumab (Herceptin®): overcoming resistance inHER2-overexpressing breast cancer models

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

(2010) Amye J. Tevaarwerk et al.   CLINICAL THERAPEUTICS

Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data

(2010) Katharina Gunzer et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

(2009) Shawn P. Fessler et al.   BREAST CANCER RESEARCH AND TREATMENT

Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy

(2009) Kaori Fujimoto-Ouchi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE